Fu L - Search Results

1

Activation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis.

Xie L, Cheng Y, Du W, Fu L, Wei Z, Guan Y, Wang Y, Mei C, Hao C, Chen M, Gu X. Xie L, et al. Among authors: fu l. Cell Death Dis. 2023 Dec 12;14(12):818. doi: 10.1038/s41419-023-06338-2. Cell Death Dis. 2023. PMID: 38086848 Free PMC article.

2

Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.

Xiong X, Fu L, Wang L, Cai H, Li L, Jiang H, Duan W, Mei C. Xiong X, et al. Among authors: fu l. Invest New Drugs. 2009 Feb;27(1):1-11. doi: 10.1007/s10637-008-9132-5. Epub 2008 May 21. Invest New Drugs. 2009. PMID: 18493719

3

Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

Xiong X, Ye Y, Fu L, Dai B, Liu J, Jia J, Tang J, Li L, Wang L, Shen J, Mei C. Xiong X, et al. Among authors: fu l. Invest New Drugs. 2009 Jun;27(3):223-32. doi: 10.1007/s10637-008-9161-0. Epub 2008 Aug 13. Invest New Drugs. 2009. PMID: 18704263

4

Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines.

Xiong X, Liu H, Fu L, Li L, Li J, Luo X, Mei C. Xiong X, et al. Among authors: fu l. Chemotherapy. 2008;54(6):463-74. doi: 10.1159/000159272. Epub 2008 Oct 2. Chemotherapy. 2008. PMID: 18832819

5

B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.

Xiong X, Zhang Y, Gao X, Dong Z, Li L, Ji C, Fu L, Luo X, Liu H, Mei C. Xiong X, et al. Among authors: fu l. Invest New Drugs. 2010 Feb;28(1):26-34. doi: 10.1007/s10637-008-9211-7. Epub 2009 Jan 13. Invest New Drugs. 2010. PMID: 19139818

6

Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

Xiong X, Wang L, Ye Y, Fu L, Chen M, Wang Q, Liu M, Tang J, Dai B, Shen J, Mei C. Xiong X, et al. Among authors: fu l. Invest New Drugs. 2010 Aug;28(4):472-81. doi: 10.1007/s10637-009-9278-9. Epub 2009 Jun 17. Invest New Drugs. 2010. PMID: 19533021

7

DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.

Liu M, Fu L, Liu C, Xiong X, Gao X, Xiao M, Cai H, Hu H, Wang X, Mei C. Liu M, et al. Among authors: fu l. Invest New Drugs. 2010 Dec;28(6):783-90. doi: 10.1007/s10637-009-9313-x. Epub 2009 Sep 16. Invest New Drugs. 2010. PMID: 19756375

8

Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.

Fu L, Xiong X, Wang L, Gao X, Ye Y, Jia J, Hu H, Li L, Shen J, Mei C. Fu L, et al. Chemotherapy. 2009;55(6):468-76. doi: 10.1159/000265529. Epub 2009 Dec 9. Chemotherapy. 2009. PMID: 19996593

9

Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.

Liu Y, Dai B, Fu L, Jia J, Mei C. Liu Y, et al. Among authors: fu l. Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):523-30. doi: 10.1111/j.1742-7843.2010.00539.x. Epub 2010 Feb 22. Basic Clin Pharmacol Toxicol. 2010. PMID: 20210794 Free article.

10

Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.

Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, Shen X, Hua Z. Dai B, et al. Among authors: fu l. Clin Sci (Lond). 2010 Jul 9;119(8):323-33. doi: 10.1042/CS20100113. Clin Sci (Lond). 2010. PMID: 20507283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,695 results

Search Page

Filters